Identification of characteristics, risk factors, and predictors of recurrent LVAD thrombosis: conditions in HeartWare devices.

Takayuki GyotenMichiel MorshuisSebastian V RojasMarcus-André DeutschRené SchrammJan F GummertHenrik Fox

Published in: Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs (2020)

Recurrent HVAD thrombosis mostly appears within 12 months after first thrombosis. Systemic t-PA therapy for recurrent pump thrombosis seems safe, achieving comparable effectiveness rates to initial t-PA therapy. Survival does not differ between patients with or without recurrent HVAD thrombosis.

Keyphrases

pulmonary embolism
risk factors
randomized controlled trial
systematic review
stem cells
left ventricular assist device
free survival
drug induced
smoking cessation